Swiss Life (SLHN VX) – FY net CHF 933m (vs cons 898m) / net premiums CHF 13.8bn (vs cons 13.84bn) / shareholder equity 7.579bn (vs cons 7.727bn) Outlook: company confirms ’08 target of CHF 1bn profit – to propose CHF 7 par value reduction – confirms target for sustainable RoE of at least 10% - announced to sell Erisa stake to HSBC France for EUR 229m (BB)

Komax (KOMN SW) – FY net 30.3m (vs cons 28m) / EBIT 38.1m (vs cons 37m) Outlook: sees favorable economic environment in ’07 – Beat Kälin to takeover as new CEO – current CEO Steiner to become chairman (BB)

Rieter (RIEN SW) – FY EBIT 239m (vs cons 219.9m) / textile 135m / automotive 111m / net profit 129m (vs cons 135.4m) Outlook: dividend increase from CHF 10 to CHF 15 – increase in sales and confident for better net (BB)

Oerlikon (OERL VX) – FY orders 2.6bn (vs cons 2.75bn) / EBIT 329m (vs cons 285m) / net profit 302m (vs cons 290m) Outlook: sees strong organic growth in ’07 – confirms 5bn sales targets for 2007 (BB)

Tamedia (TAMN SW) – FY sales 723.6m (vs cons 728.8m) / EBIT 112.2m (vs cons 116.5m) / net profit 98.4m (vs cons 96.2m) Outlook: raises dividend to CHF 3 – expect a slowdown and only a small advance in commercial advertising (BB)

Kuoni (KUNN SW) – nominates Beeser, Karrer & Lindquist to board, says Boppe to step down (BB)

Roche (ROG VX) – submits supplemental new drug application to the FDA for the use of Xeloda in combination with oxaliplatin “Xelox” with our without Avastin in the treatment of metastic colorectal cancer (BB)